245 related articles for article (PubMed ID: 9261415)
21. Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency.
Davenport MG; Pagano JS
J Virol; 1999 Apr; 73(4):3154-61. PubMed ID: 10074167
[TBL] [Abstract][Full Text] [Related]
22. Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor.
Sung NS; Wilson J; Davenport M; Sista ND; Pagano JS
Mol Cell Biol; 1994 Nov; 14(11):7144-52. PubMed ID: 7935429
[TBL] [Abstract][Full Text] [Related]
23. The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive.
Tao Q; Robertson KD; Manns A; Hildesheim A; Ambinder RF
J Virol; 1998 Sep; 72(9):7075-83. PubMed ID: 9696800
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus nuclear antigen-1-dependent and -independent oriP-binding cellular proteins.
Kusano S; Tamada K; Senpuku H; Harada S; Ito S; Yanagi K
Intervirology; 2001; 44(5):283-90. PubMed ID: 11684889
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates.
Ruf IK; Moghaddam A; Wang F; Sample J
J Virol; 1999 Mar; 73(3):1980-9. PubMed ID: 9971778
[TBL] [Abstract][Full Text] [Related]
26. Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site.
Zhao B; Sample CE
J Virol; 2000 Jun; 74(11):5151-60. PubMed ID: 10799590
[TBL] [Abstract][Full Text] [Related]
27. High-resolution analysis of CpG methylation and in vivo protein-DNA interactions at the alternative Epstein-Barr virus latency promoters Qp and Cp in the nasopharyngeal carcinoma cell line C666-1.
Bakos A; Banati F; Koroknai A; Takacs M; Salamon D; Minarovits-Kormuta S; Schwarzmann F; Wolf H; Niller HH; Minarovits J
Virus Genes; 2007 Oct; 35(2):195-202. PubMed ID: 17510783
[TBL] [Abstract][Full Text] [Related]
28. Unique Epstein-Barr virus (EBV) latent gene expression, EBNA promoter usage and EBNA promoter methylation status in chronic active EBV infection.
Yoshioka M; Kikuta H; Ishiguro N; Ma X; Kobayashi K
J Gen Virol; 2003 May; 84(Pt 5):1133-1140. PubMed ID: 12692278
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa.
Robertson ES; Grossman S; Johannsen E; Miller C; Lin J; Tomkinson B; Kieff E
J Virol; 1995 May; 69(5):3108-16. PubMed ID: 7707539
[TBL] [Abstract][Full Text] [Related]
30. Human p32: a coactivator for Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent cycle DNA replication.
Van Scoy S; Watakabe I; Krainer AR; Hearing J
Virology; 2000 Sep; 275(1):145-57. PubMed ID: 11017796
[TBL] [Abstract][Full Text] [Related]
31. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
Ling PD; Hsieh JJ; Ruf IK; Rawlins DR; Hayward SD
J Virol; 1994 Sep; 68(9):5375-83. PubMed ID: 8057421
[TBL] [Abstract][Full Text] [Related]
32. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.
Sample J; Henson EB; Sample C
J Virol; 1992 Aug; 66(8):4654-61. PubMed ID: 1321268
[TBL] [Abstract][Full Text] [Related]
33. Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1.
Hahn AM; Huye LE; Ning S; Webster-Cyriaque J; Pagano JS
J Virol; 2005 Aug; 79(15):10040-52. PubMed ID: 16014964
[TBL] [Abstract][Full Text] [Related]
34. Analysis of Epstein-Barr virus (EBV) nuclear antigen 1 subtypes in EBV-associated lymphomas from Brazil and the United Kingdom.
MacKenzie J; Gray D; Pinto-Paes R; Barrezueta LFM; Armstrong AA; Alexander FA; McGeoch DJ; Jarrett RF
J Gen Virol; 1999 Oct; 80 ( Pt 10)():2741-2745. PubMed ID: 10573169
[TBL] [Abstract][Full Text] [Related]
35. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF
Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213
[TBL] [Abstract][Full Text] [Related]
36. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
37. DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines.
Sauder C; Haiss P; Grässer FA; Zimber-Strobl U; Mueller-Lantzsch N
J Gen Virol; 1994 Nov; 75 ( Pt 11)():3067-79. PubMed ID: 7964616
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus gene expression in interferon-treated cells. Implications for the regulation of protein synthesis and the antiviral state.
Clarke PA; Sharp NA; Arrand JR; Clemens MJ
Biochim Biophys Acta; 1990 Aug; 1050(1-3):167-73. PubMed ID: 2169891
[TBL] [Abstract][Full Text] [Related]
39. Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation.
Harada S; Yalamanchili R; Kieff E
J Virol; 1998 Dec; 72(12):9948-54. PubMed ID: 9811732
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation.
Harada S; Kieff E
J Virol; 1997 Sep; 71(9):6611-8. PubMed ID: 9261383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
